Piper Jaffray Companies set a $111.00 price objective on Neurocrine Biosciences (NASDAQ:NBIX) in a research report report published on Tuesday. The brokerage currently has a buy rating on the stock. Piper Jaffray Companies also issued estimates for Neurocrine Biosciences’ Q4 2018 earnings at $0.11 EPS, FY2018 earnings at $0.14 EPS, Q1 2019 earnings at $0.24 EPS, Q2 2019 earnings at $0.44 EPS, Q3 2019 earnings at $0.52 EPS, Q4 2019 earnings at $0.64 EPS, FY2019 earnings at $1.85 EPS, FY2020 earnings at $4.47 EPS, FY2021 earnings at $5.73 EPS and FY2022 earnings at $8.15 EPS.

A number of other brokerages have also recently issued reports on NBIX. Cantor Fitzgerald initiated coverage on shares of Neurocrine Biosciences in a research note on Wednesday, August 22nd. They issued an overweight rating and a $150.00 price objective for the company. HC Wainwright reissued a buy rating and issued a $162.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, August 1st. Oppenheimer set a $128.00 price objective on shares of Neurocrine Biosciences and gave the stock a buy rating in a research note on Tuesday, July 31st. BidaskClub raised shares of Neurocrine Biosciences from a hold rating to a buy rating in a research note on Friday, July 27th. Finally, ICAP reduced their price objective on shares of Neurocrine Biosciences from $140.00 to $128.00 and set an outperform rating for the company in a research note on Tuesday, September 4th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $124.88.

NBIX stock traded down $2.90 during midday trading on Tuesday, reaching $105.41. 744,889 shares of the company’s stock traded hands, compared to its average volume of 776,003. Neurocrine Biosciences has a 52-week low of $67.32 and a 52-week high of $126.98. The stock has a market cap of $9.84 billion, a P/E ratio of 2,170.00, a P/E/G ratio of 34.87 and a beta of 0.94.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, November 5th. The company reported $0.52 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The business had revenue of $151.80 million during the quarter, compared to analysts’ expectations of $151.51 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The firm’s revenue was up 149.7% on a year-over-year basis. On average, sell-side analysts predict that Neurocrine Biosciences will post 0.17 earnings per share for the current year.

In related news, Director Richard F. Pops sold 5,500 shares of the company’s stock in a transaction on Monday, October 29th. The shares were sold at an average price of $107.13, for a total transaction of $589,215.00. Following the completion of the transaction, the director now owns 37,759 shares in the company, valued at $4,045,121.67. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gary A. Lyons sold 15,000 shares of the company’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $114.41, for a total transaction of $1,716,150.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,500 shares of company stock valued at $3,295,455. 4.30% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the stock. Trexquant Investment LP bought a new position in shares of Neurocrine Biosciences during the third quarter worth $2,088,000. Opera Trading Capital bought a new position in shares of Neurocrine Biosciences during the third quarter worth $449,000. Fosun International Ltd bought a new position in shares of Neurocrine Biosciences during the third quarter worth $5,193,000. Jennison Associates LLC lifted its position in Neurocrine Biosciences by 0.9% during the third quarter. Jennison Associates LLC now owns 403,968 shares of the company’s stock valued at $49,668,000 after purchasing an additional 3,556 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. bought a new position in Neurocrine Biosciences during the third quarter valued at $793,000.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

See Also: Hedge Funds Explained

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.